论文信息 - Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial - 字舞流文

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

Michael L. Wang | C. Cleeland | T. Mendoza | R. Orlowski | M. Qazilbash | R. Champlin | Z. Berková | Sheeba K. Thomas | J. Shah | D. Weber | S. Thomas | M. Wang | J. J. Shah | Lei Feng | L. Feng